Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

EyeTechCare Doubles the Number of Health Care Facilities in France with the EyeOP1 Device

Published: Thursday, January 02, 2014
Last Updated: Wednesday, January 01, 2014
Bookmark and Share
The EyeOp1 device is now available in ten centers across France, with this figure expected to double in 2014.

EyeTechCare SA has announced that six more health care facilities in France now have the new EyeOP1 device.

With the four centers of excellence set up in June 2013, the number of devices installed across the country now stands at ten, bringing this new therapeutic alternative for glaucoma to a larger number of patients.

During 2013 an estimated 300 patients in France have benefited from the technique. The number should exceed 1,000 patients in 2014.

Lille and Grenoble university hospitals and the Saint Joseph and XV-XX hospitals in Paris were the first centers to have the device installed last June. EyeOP1 technology is also now available at the Val de Grace hospital in Paris, the Croix Rousse hospital in Lyon, the Sourdille clinic in Nantes, the Pasteur and Saint Nicolas clinics in Toulouse and the Aguilera clinic in Biarritz.

A further ten centers in France are currently trialling the device. Between now and the end of 2014, a total of 20 glaucoma treatment referral centers should be able to offer this new, non-invasive therapy based on high-intensity focused ultrasound (HIFU).

Known as UC3, the treatment is a promising therapeutic innovation. The idea behind it is a world first resulting from a collaborative effort by EyeTechCare, INSERM (the French national institute for health and medical research) and internationally-renowned clinicians.

For the moment, UC3 therapy is restricted to particular types of patient whose current treatment is failing. The technique is entirely non-invasive, quick and accurate. It has been proven as an effective means of reducing internal eye pressure in some patients and is very well tolerated.

Each health care facility's decision to acquire this technology is based on the benefit to patients: when UC3 can be offered as an alternative to surgery, it is better for the patients. Following three years of international clinical research involving 160 patients, ophthalmologists who use this method now know when it should be offered. It gives patients whose current treatment is failing another chance to preserve their sight without the usual risks associated with traditional techniques. Further work involving several hundred patients is underway to refine the scope of application for UC3 therapy.

French hospitals are in charge of the treatment for eligible patients and use of this innovative technology in health care facilities is now funded under an existing reimbursement.

Fabrice Romano, CEO of EyeTechCare, welcomes the development: "Facilities which already have UC3 technology have shown genuine willingness to offer their patients the latest therapeutic innovations, without being deterred by the cost of the device. Nonetheless, 2014 will see EyeTechCare commence the regulatory proceedings required for the health authorities to classify the EyeOP1 device appropriately and, potentially, to re-evaluate it."

EyeTechCare is poised to pursue the extension of its network of EyeOP1 users to the rest of Europe. One system is already set up in Lausanne, Switzerland and another is newly installed in Barcelona, Spain. Furthermore, special premium reimbursement was recently granted in the Andalusia region of Spain in recognition of the innovative and potentially cost-saving nature of the UC3 procedure.

A significant number of carefully selected glaucoma reference centres are currently trialing the product in eight Western European countries from Scandinavia to Portugal. Further to strong interest earlier this year the company plans to install another ten systems across Spain and Italy during 2014.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EyeTechCare Focused Ultrasound Treatment Device Gains CE Mark Extension
Use of the EyeOP1® device is now open to less advanced glaucoma.
Friday, February 06, 2015
EyeTechCare Raises EUR Ten Million in a Third Round of Funding
The funding will be used to complete the EyeTechCare EyeMUST 2 international clinical trial and to start the FDA registration process.
Thursday, July 04, 2013
EyeTechCare Announces Preliminary Results for EyeMUST
Good efficacy and tolerance confirm pilot study results and will allow launch of novel ultrasound-based system in the fourth quarter 2012.
Monday, July 02, 2012
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Alzheimer’s Linked Protein Can Be Removed From Brain Without Hindering Memory, Learning
Researchers at UTSW have found that the mice can maintain their learning and memory when virtually all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos